Drugs / TOL2506
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05645536 | Dec 2022 → Jun 2028 expected | breast cancer | Tolmar Inc. | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04906395 | Jul 2021 → Apr 2026 overdue | female breast carcinoma | Tolmar Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOL2506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04906395 ↗ |
| Known as | Leuprolide Acetate | “Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.” NCT04906395 ↗ |
| Route | Subcutaneous | “Subcutaneous injection every 3 months.” NCT04906395 ↗ |